Michael S. Gordon - Dec 25, 2023 Form 3 Insider Report for ProMIS Neurosciences Inc. (PMN)

Role
10%+ Owner
Signature
/s/ Michael S. Gordon
Stock symbol
PMN
Transactions as of
Dec 25, 2023
Transactions value $
$0
Form type
3
Date filed
12/27/2023, 06:02 AM
Next filing
Aug 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PMN Common Shares, no par value 1.11M Dec 25, 2023 By Title 19 Promis F1
holding PMN Common Shares, no par value 48.3K Dec 25, 2023 By Title 19 Acies F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PMN Warrants to Purchase Common Shares, no par value Dec 25, 2023 Common Shares 51.6K By Title 19 Promis F1, F3
holding PMN Warrants to Purchase Common Shares, no par value Dec 25, 2023 Common Shares 26.6K By Title 19 Promis F1, F4
holding PMN Warrants to Purchase Common Shares, no par value Dec 25, 2023 Common Shares 798K By Title 19 Promis F1, F5
holding PMN Series 2 Preferred Shares, no par value Dec 25, 2023 Common Shares 500K By Title 19 Promis F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
F2 By Title 19 Acies, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
F3 Consists of 51,562 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $0.21 per whole warrant. These warrants are currently exercisable and expire on August 24, 2026.
F4 Consists of 26,597 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $7.50 per whole warrant. These warrants are part of Units, each consisting of one Common Share and one-quarter of one warrant to purchase one Common Share. The purchase price for each Unit was $5.40. These warrants are currently exercisable and expire on April 11, 2028, the fifth anniversary of the date the warrants first became exercisable.
F5 Consists of 797,872 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $1.75 per whole warrant beginning February 23, 2024. These warrants expire on February 23, 2029, the fifth anniversary of the date the warrants first become exercisable.
F6 The Series 2 Preferred Shares are nonvoting and noninterest bearing and are currently convertible at a 1:1 ratio into Common Shares at the option of the holder. The Series 2 Preferred Shares will involuntarily convert into Common Shares upon cumulative qualified equity financing in excess of $14 million.